TABLE 2.

Selection of cases and controls for assessment of breadth and potency of NAb responses

Group and caseCase time point (ypi)Case VL (log10 copies/ml)Control time point mean (ypi)aControl VL mean (log10 copies/ml)
Cases at ∼1 year
QA0130.725.120.764.79
QB0080.834.510.864.50
QA4130.765.600.974.70
QB0451.94.491.94.24
QB7261.33.901.13.88
QD0221.2NDb1.24.47
Presuperinfection cases
QA0130.725.120.764.79
QB0080.834.510.864.50
QA4132.04.942.04.91
QB0454.63.784.74.93
QB7262.81.702.84.08
QD0225.03.815.04.67
  • a For each case, 3 controls per case were matched according to HIV-1 subtype, timing of plasma samples tested, and VLs. Insufficient data were available to compare CD4 counts between cases and controls.

  • b ND, not done.